<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606512</url>
  </required_header>
  <id_info>
    <org_study_id>CR108465</org_study_id>
    <secondary_id>2017-003859-36</secondary_id>
    <secondary_id>VAC18194RSV2002</secondary_id>
    <nct_id>NCT03606512</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age</brief_title>
  <official_title>A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and reactogenicity of an intramuscular
      regimen of 3 doses of 2.5*10^10 viral particles (vp) of adenovirus serotype 26 based
      respiratory syncytial virus pre-fusion protein (Ad26.RSV.preF) vaccine in RSV-seronegative
      toddlers aged 12 to 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RSV is considered the most important cause of serious acute respiratory illness in children
      under 5 years of age. Ad26.RSV.preF (JNJ-64400141) investigational vaccine is a
      replication-incompetent serotype 26 adenoviral vector (Ad26) containing a deoxyribonucleic
      acid (DNA) transgene that encodes for the F protein derived from the respiratory syncytial
      virus (RSV) A2 strain stabilized in the pre-fusion conformation (Ad26.RSV.preF). The study
      will evaluate whether Ad26.RSV.preF is safe, well-tolerated, and immunogenic in
      RSV-seronegative toddlers. The study will have 3 phases: a screening phase (up to 6 weeks
      before the first dose), a vaccination phase (34 weeks), and a safety follow-up phase through
      2 RSV seasons after the first dose. RSV infection will be monitored by active and passive
      surveillance. The total duration of the study will be approximately 26 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Solicited Local and Systemic Adverse Events (AEs) After Vaccination</measure>
    <time_frame>7 days after each vaccination (up to Day 64)</time_frame>
    <description>Number of participants with solicited local and systemic AEs will be evaluated. Solicited local AEs (including erythema, swelling/induration, and pain/tenderness at the study vaccine injection site) and solicited systemic AEs (fatigue, headache, myalgia, arthralgia, chills, nausea and fever) will be noted in the participant diary after 7 days of each vaccination. Local and systemic AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Unsolicited AEs</measure>
    <time_frame>28 days after each vaccination (up to Day 85)</time_frame>
    <description>Number of participants with unsolicited AEs will be evaluated. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Unsolicited AEs will include all AEs for which the participant is not specifically questioned in the participant diary. Unsolicited AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>First vaccination to the end of the study (approximately up to 26 months)</time_frame>
    <description>Number of participants with SAEs will be evaluated. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life threatening experience, is a congenital anomaly/birth defect, is suspected transmission of any infectious agent via a medicinal product, is medically important, and may jeopardize participant or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibodies to Respiratory Syncytial Virus (RSV) A Strain</measure>
    <time_frame>Days 1, 8, 85, and 267 (End of season [EOS])</time_frame>
    <description>RSV neutralizing titers of the vaccine-induced immune response will be assessed for detection of neutralizing antibodies to RSV A strain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV Fusion Protein (F-protein) Enzyme-linked Immunosorbent Assay (ELISA)</measure>
    <time_frame>Days 1, 8, 85, and 267 (EOS)</time_frame>
    <description>Antibodies binding to RSV F-protein in pre-fusion and post-fusion forms will be assessed by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-Cell Responses Measured by Flow Cytometry (Intracellular cytokine Staining [ICS])</measure>
    <time_frame>Days 1 and 85</time_frame>
    <description>T-cell responses to RSV F-protein peptides for T-helper cells (Th1/Th2) subtyping will be measured by flow cytometry (ICS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Severe RSV-Lower Respiratory Tract Infection (LRTI)</measure>
    <time_frame>Approximately up to 26 months</time_frame>
    <description>Number of participants with severe RSV-LRTI will be assessed. Severe RSV-LRTI will be defined as the presence of severe LRTI as assessed by the Clinical Endpoint Committee (CEC), and confirmation of RSV infection from a nasal (mid-turbinate or nasopharyngeal) sample using reverse transcriptase polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>Group 1: RSV Seronegative Toddlers (Ad26.RSV.preF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Respiratory syncytial virus (RSV) seronegative toddlers will receive intramuscular (IM) injection of 2.5*10^10 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F-protein on Days 1, 29, and 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: RSV Seronegative Toddlers (Placebo/Nimenrix)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RSV seronegative toddlers will receive IM injection of placebo on Days 1, 29 and 57. Placebo can be replaced with Nimenrix on Day 57 in countries where applicable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.RSV.preF</intervention_name>
    <description>Ad26.RSV.preF will be administered as IM injection at a dose of 2.5*10^10 vp.</description>
    <arm_group_label>Group 1: RSV Seronegative Toddlers (Ad26.RSV.preF)</arm_group_label>
    <other_name>JNJ-64400141</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.</description>
    <arm_group_label>Group 2: RSV Seronegative Toddlers (Placebo/Nimenrix)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nimenrix</intervention_name>
    <description>Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.</description>
    <arm_group_label>Group 2: RSV Seronegative Toddlers (Placebo/Nimenrix)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant who is seronegative for respiratory syncytial virus (RSV) within 42 days
             prior to dosing

          -  Participant is the product of a normal term pregnancy greater than or equal to (&gt;=)37
             weeks, with a minimum birth weight of 2.5 kilogram (kg)

          -  Participant must be in good health without any significant medical illness on the
             basis of physical examination, medical history, and vital signs performed at screening

          -  Participant has received all routine immunizations appropriate for his or her age
             according to local guidelines

          -  Each participant's parent(s)/legal guardian(s) must have access to a consistent means
             of contact either by telephone contact or email/computer

        Exclusion Criteria:

          -  Participant's weight is below tenth percentile according to World Health Organization
             (WHO) pediatric growth and weight charts

          -  Participant has any clinically significant acute or chronic medical condition (for
             example, history of seizure disorders, bleeding/clotting disorder, autoimmune disease,
             active malignancy, systemic infections, congenital heart disease, history of any
             pulmonary condition requiring medication, atopy, reactive airway disease,
             medically-confirmed wheezing, bronchoconstriction or treatment with a beta 2 agonist,
             cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease,
             medically-confirmed apnea, hospitalization for respiratory illness, or mechanical
             ventilation for respiratory illness) that, in the opinion of the investigator, would
             preclude participation

          -  Participant is in receipt of, or planning to receive, live attenuated vaccine (for
             example, measles, mumps and rubella [MMR] or varicella, but excluding rotavirus
             vaccine) within 28 days of each study vaccination (that is, before and after); other
             vaccines (for example, influenza, pertussis, polio or rotavirus) should be given at
             least 14 days before or 14 days after each study vaccination

          -  Participant has known or suspected immunodeficiency, such as known human
             immunodeficiency virus (HIV) infection

          -  Participant has a known allergy to vaccines or vaccine components (including any of
             the constituents of the study vaccine), or history of anaphylaxis or other serious
             adverse reactions to vaccines or vaccine components (including any of the constituents
             of the study vaccine). Participants with egg allergies can be enrolled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barwon Health</name>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Telethon Kids Institute</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospital de Clinicas - UFPR</name>
      <address>
        <city>Curitiba</city>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pequeno Principe</name>
      <address>
        <city>Curitiba</city>
        <zip>80250-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-074</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610 - 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Vaccine Study Centre</name>
      <address>
        <city>Pierrefonds</city>
        <zip>H9H 4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Québec Université Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Järvenpään rokotetutkimusklinikka</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen rokotetutkimusklinikka</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turun rokotetutkimusklinikka</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jerzy Brzostek Prywatny Gabinet Lekarski</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital im. Swietej Jadwigi Slaskiej, Oddział Pediatryczny z Pododdziałem Niemowlęcym</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sachsska barn-och ungdomssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>11861</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W21PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO166YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108465</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

